Activated protein C inhibits bisphosphonate-induced endothelial cell death via the endothelial protein C receptor and nuclear factor-κB pathways

International Journal of Molecular Medicine

Volumn 27, Issue 6, 2011, Pages 835-840

  Seol, Jae Won ^a,b   Lee, You Jin ^a   Jackson, Christopher J ^b   Sambrook, Philip N ^b   Park, Sang Youel ^a  

^a Chonbuk National University   (South Korea)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Activated protein C; Bisphosphonates; Caspase 3; Endothelial protein c receptor; Nuclear factor b

Indexed keywords

ACTIVATED PROTEIN C; ALENDRONIC ACID; CASPASE 3; ENDOTHELIAL PROTEIN C RECEPTOR; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE INJURY; BONE METASTASIS; CELL DAMAGE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ANTIGENS, CD; CELL DEATH; CELL NUCLEUS; DIPHOSPHONATES; ENDOTHELIAL CELLS; HUMANS; NF-KAPPA B; PROTEIN C; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 79954466828     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.649     Document Type: Article

References (39)

1. Fukudome K and Esmon CT: Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269: 26486-26491, 1994. (Pubitemid 24328474)
2. Xue M, Campbell D, Sambrook PN, Fukudome K and Jackson CJ: Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 125: 1279-1285, 2005.
3. Mosnier LO, Zlokovic BV and Griffin JH: The cytoprotective protein C pathway. Blood 109: 3161-3172, 2007.
4. Okajima K: Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr Vasc Pharmacol 2: 125-133, 2004.
5. Yuksel M, Okajima K, Uchiba M, Horiuchi S and Okabe H: Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 88: 267-273, 2002. (Pubitemid 34873708)
6. Cheng T, Liu D, Griffin JH, et al: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9: 338-342, 2003. (Pubitemid 36362790)
7. Joyce DE, Gelbert L, Ciaccia A, DeHoff B and Grinnell BW: Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11199-11203, 2001. (Pubitemid 38089304)
8. Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist 11: 1121-1131, 2006.
9. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC and Drayson MT: Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113: 1035-1043, 2001. (Pubitemid 32634773)
10. Reginster JY and Sarlet N: The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol 5: 15-23, 2006.
11. Boissier S, Magnetto S, Frappart L, et al: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894, 1997. (Pubitemid 27427670)
12. Stearns ME and Wang M: Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 16: 693-702, 1998. (Pubitemid 29170479)
13. Fournier P, Boissier S, Filleur S, et al: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544, 2002. (Pubitemid 35364119)
14. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001. (Pubitemid 32448513)
15. Wakchoure S, Merrell MA, Aldrich W, et al: Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12: 2862-2868, 2006.
16. Migliorati CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21: 4253-4254, 2003.
17. Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534, 2004. (Pubitemid 38542516)
18. Lodder MC, Van Pelt PA, Lems WF, Kostense PJ, Koks CH and Dijkmans BA: Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. J Rheumatol 30: 2080-2081, 2003.
19. Valleala H, Laasonen L, Koivula MK, et al: Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 30: 468-473, 2003. (Pubitemid 36301936)
20. Nachman RL and Jaffe EA: Endothelial cell culture: beginnings of modern vascular biology. J Clin Invest 114: 1037-1040, 2004. (Pubitemid 39578688)
21. Herron GS, Banda MJ, Clark EJ, Gavrilovic J and Werb Z: Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 261: 2814-2818, 1986. (Pubitemid 17218297)
22. Russell RG: Bisphosphonates: from bench to bedside. Ann NY Acad Sci 1068: 367-401, 2006.
23. Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91: 1191-1200, 2001.
24. Xue M, Smith MM, Little CB, Sambrook P, March L and Jackson CJ: Activated protein C mediates a healing phenotype in cultured tenocytes. J Cell Mol Med 13: 749-757, 2009.
25. Xue M, Thompson P, Kelso I and Jackson C: Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Exp Cell Res 299: 119-127, 2004. (Pubitemid 39078387)
26. Jackson CJ, Xue M, Thompson P, et al: Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 13: 284-294, 2005. (Pubitemid 40848022)
27. Riewald M, Petrovan RJ, Donner A, Mueller BM and Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880-1882, 2002.
28. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K and Namiki M: Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol 13: 593-600, 2006. (Pubitemid 43760426)
29. Rachner TD, Singh SK, Schoppet M, et al: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287: 109-116, 2010.
30. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
31. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997. (Pubitemid 27163860)
32. Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K and Hirata M: The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 146: 633-641, 2005. (Pubitemid 41573614)
33. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E and Wolf D: The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91: 1165-1171, 2006. (Pubitemid 44408425)
34. Xue M, March L, Sambrook PN and Jackson CJ: Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis Rheum 56: 2864-2874, 2007. (Pubitemid 47502732)
35. Cunnane G, FitzGerald O, Hummel KM, et al: Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 44: 1744-1753, 2001. (Pubitemid 32758219)
36. Konttinen YT, Ainola M, Valleala H, et al: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 58: 691-697, 1999. (Pubitemid 29517255)
37. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I and Overall CM: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289: 1202-1206, 2000. (Pubitemid 30650734)
38. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I and Overall CM: Matrix metalloproteinase processing of monocyte chemo attractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100: 1160-1167, 2002. (Pubitemid 34864266)
39. Lai TJ, Hsu SF, Li TM, et al: Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 28: 1231-1235, 2007.